Verisante Technology, Inc.

Verisante Technology, Inc.

September 30, 2013 14:34 ET

Verisante Technology, Inc. Exhibits at the 22nd Congress of the European Academy of Dermatology in Istanbul, Turkey

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 30, 2013) - Verisante Technology, Inc. (TSX VENTURE:VRS) (OTCQX:VRSEF) (FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company is exhibiting at the 22nd Congress of the European Academy of Dermatology and Venereology ("EADV") in Istanbul, Turkey, from October 3-6, 2013. Over 8,000 participants are expected at the EADV's 22nd Annual Congress.

The Company will be demonstrating Aura™, an innovative device for the detection of all major forms of skin cancer and precancerous lesions, in support of sales and marketing efforts in Europe. Interested parties are invited to view Aura™ at our Exhibit Booth #31.

The European medical device market is the second largest in the world, worth over $78 billion and representing 30 per cent of the world market - second only to the United States. Last year, Aura™ received the Conformite Europeenne (CE) Mark approval. CE Mark is recognized by all the 27 Member States of the EU.

Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma, basal cell carcinoma, and/or actinic keratosis when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.

About the European Academy of Dermatology and Venereology

The EADV is a non-profit association, founded in 1987, whose mission is to advance excellence in clinical care, research, education and training in the field of dermatology and Venereology and to act as the advocate and educator of patients particularly those with cutaneous or venereal diseases.

The EADV organizes annually one main congress in one of the European capitals and one spring meeting, offers training, fostering courses and online teaching for continuing medical education.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.

Verisante Aura™ was awarded Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

Contact Information